Por favor, use este identificador para citar o enlazar este ítem: https://www.arca.fiocruz.br/handle/icict/55854

Tipo
Artículo
Derechos de autor
Acceso abierto
Colecciones
Compartir

Estadísticas
Metadatos
Mostrar el registro completo del ítem

IMMUNOCOMPROMISED PATIENTS HAVE BEEN NEGLECTED IN COVID-19 TRIALS: A CALL FOR ACTION
Trøseid, Marius et al. | Fecha del documento: 2022
Autor
Trøseid, Marius
Hentzien, Maxime
Ader, Florence
Cardoso, Sandra Wagner
Arribas, Jose R.
Molina, Jean-Michel
Mueller, Nicolas
Hites, Maya
Bonnet, Fabrice
Manuel, Oriol
Costagliola, Dominique
Grinsztejn, Beatriz
Olsen, Inge Christoffer
Yazdapanah, Yazdan
Calmy, Alexandra
Afiliación
Oslo University Hospital. Section of Clinical Immunology and Infectious Diseases. Oslo, Norway.
Geneva University Hospitals. HIV/AIDS Research Unit. Geneva, Switzerland.
Hospices Civils de Lyon. Hôpital de la Croix-Rousse. Département des Maladies Infectieuses et Tropicales. Lyon, France.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Pesquisa Clínica em DST/AIDS. Rio de Janeiro, RJ, Brasil.
Hospital La Paz. Infectious Diseases Unit. Madrid, Spain.
Saint-Louis APHP. Infectious Diseases Department. Paris, France.
University Hospital. Division of Infectious Diseases. Zurich, Switzerland.
Cliniques Universitaires de Bruxelles-Hôpital Érasme. Université Libre de Bruxelles. Clinique des Maladies Infectieuses. Brussels, Belgium.
CHU de Bordeaux and Université de Bordeaux. Bordeaux, France.
Lausanne University Hospital. Infectious Diseases Service. Lausanne, Switzerland.
Sorbonne Université. Institut Pierre Louis d'Epidémiologie et de Santé Publique. Paris, France.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Pesquisa Clínica em DST/AIDS. Rio de Janeiro, RJ, Brasil.
Oslo University Hospital. Section of Clinical Immunology and Infectious Diseases. Oslo, Norway.
Université de Paris. Paris, France.
Geneva University Hospitals. HIV/AIDS Research Unit. Geneva, Switzerland.
Resumen en ingles
Although several innovative and repurposed drugs have been approved for the treatment of COVID-19 during the last year, we still do not have evidence-based knowledge on the best therapeutic strategy to treat immunocompromised patients. Most treatment guidelines are structured to whether the disease state is mild, moderate, or severe, and not sufficiently according to host factors including host immunity. Whereas the Omicron variant causes less severe diseases in the general population, this is not necessarily the case for individuals with an impaired immune system, such as organ transplant recipients, patients with hematological malignancies, active cancer or primary immunodeficiency, or individuals treated with immunosuppressive drugs for a variety of medical conditions.
Palabras clave en ingles
COVID-19
Antivirals
Guidelines
Immunocompromised
Trials
 
Editor
Elsevier
Referencia
TRØSEID, Marius et al. Immunocompromised patients have been neglected in COVID-19 trials: a call for action. Clinical microbiology and infection, v. 28, n. 9, p. 1182-1183, 2022.
Versión posterior
https://www.arca.fiocruz.br/handle/icict/53896
DOI
10.1016/j.cmi.2022.05.005
ISSN
1469-0691
Notas
Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.